WO2006000448A3 - Fc-INTERFERON-BETA FUSION PROTEINS - Google Patents

Fc-INTERFERON-BETA FUSION PROTEINS Download PDF

Info

Publication number
WO2006000448A3
WO2006000448A3 PCT/EP2005/006925 EP2005006925W WO2006000448A3 WO 2006000448 A3 WO2006000448 A3 WO 2006000448A3 EP 2005006925 W EP2005006925 W EP 2005006925W WO 2006000448 A3 WO2006000448 A3 WO 2006000448A3
Authority
WO
WIPO (PCT)
Prior art keywords
fusion proteins
interferon
beta
ifn
nucleic acid
Prior art date
Application number
PCT/EP2005/006925
Other languages
French (fr)
Other versions
WO2006000448A2 (en
Inventor
Stephen D Gillies
Nigel John Watkins
Matthew Paul Baker
King-Ming Lo
Original Assignee
Merck Patent Gmbh
Stephen D Gillies
Nigel John Watkins
Matthew Paul Baker
King-Ming Lo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh, Stephen D Gillies, Nigel John Watkins, Matthew Paul Baker, King-Ming Lo filed Critical Merck Patent Gmbh
Priority to AT05766761T priority Critical patent/ATE443720T1/en
Priority to AU2005256519A priority patent/AU2005256519B2/en
Priority to CA2572015A priority patent/CA2572015C/en
Priority to EP05766761A priority patent/EP1761559B1/en
Priority to DE602005016799T priority patent/DE602005016799D1/en
Priority to JP2007517216A priority patent/JP4808709B2/en
Publication of WO2006000448A2 publication Critical patent/WO2006000448A2/en
Publication of WO2006000448A3 publication Critical patent/WO2006000448A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

Disclosed are Fc-interferon-beta (Fc-IFN-β) fusion proteins and nucleic acid molecules encoding them. The Fc- IFN-β fusion proteins include variants of the interferon-beta (IFN-β) protein that are altered to achieve enhanced biological activity, prolonged circulating half-life and greater solubility. Also disclosed are methods of producing the fusion proteins and methods of using the fusion proteins and/or nucleic acid molecules for treating diseases and conditions alleviated by the administration of interferon-beta.
PCT/EP2005/006925 2004-06-28 2005-06-28 Fc-INTERFERON-BETA FUSION PROTEINS WO2006000448A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AT05766761T ATE443720T1 (en) 2004-06-28 2005-06-28 FC-INTERFERON-BETA FUSION PROTEINS
AU2005256519A AU2005256519B2 (en) 2004-06-28 2005-06-28 Fc-interferon-beta fusion proteins
CA2572015A CA2572015C (en) 2004-06-28 2005-06-28 Fc-interferon-beta fusion proteins
EP05766761A EP1761559B1 (en) 2004-06-28 2005-06-28 Fc-INTERFERON-BETA FUSION PROTEINS
DE602005016799T DE602005016799D1 (en) 2004-06-28 2005-06-28 FC INTERFERON BETA FUSION PROTEINS
JP2007517216A JP4808709B2 (en) 2004-06-28 2005-06-28 Fc-interferon-beta fusion protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58338904P 2004-06-28 2004-06-28
US60/583,389 2004-06-28

Publications (2)

Publication Number Publication Date
WO2006000448A2 WO2006000448A2 (en) 2006-01-05
WO2006000448A3 true WO2006000448A3 (en) 2006-03-02

Family

ID=35429166

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/006925 WO2006000448A2 (en) 2004-06-28 2005-06-28 Fc-INTERFERON-BETA FUSION PROTEINS

Country Status (9)

Country Link
US (3) US7670595B2 (en)
EP (1) EP1761559B1 (en)
JP (1) JP4808709B2 (en)
AT (1) ATE443720T1 (en)
AU (1) AU2005256519B2 (en)
CA (1) CA2572015C (en)
DE (1) DE602005016799D1 (en)
ES (1) ES2332924T3 (en)
WO (1) WO2006000448A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103570836A (en) * 2013-10-25 2014-02-12 江苏众红生物工程创药研究院有限公司 Recombinant porcine interferon beta1-Fc fusion protein as well as encoding gene and expressing method thereof
CN104530213A (en) * 2014-11-24 2015-04-22 广西大学 Viral hepatitis treatment drug interferon production technology

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60122286T2 (en) 2000-02-11 2007-08-02 Merck Patent Gmbh INCREASING THE CIRCULATORY HALF-TIME OF ANTIBODY-BASED FUSION PROTEINS
CA2440221C (en) 2001-03-07 2013-02-05 Merck Patent Gesellschaft Mit Beschraenkter Haftung Expression technology for proteins containing a hybrid isotype antibody moiety
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
DE60239454D1 (en) 2001-05-03 2011-04-28 Merck Patent Gmbh RECOMBINANT, TUMOR-SPECIFIC ANTIBODY AND ITS USE
WO2003048334A2 (en) 2001-12-04 2003-06-12 Merck Patent Gmbh Immunocytokines with modulated selectivity
WO2005063820A2 (en) 2003-12-30 2005-07-14 Merck Patent Gmbh Il-7 fusion proteins
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
KR20070085886A (en) * 2004-12-09 2007-08-27 메르크 파텐트 게엠베하 Il-7 variants with reduced immunogenicity
CN101184771A (en) * 2005-05-26 2008-05-21 先灵公司 Interferon-igg fusion
US7566456B2 (en) * 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
JP5175214B2 (en) * 2005-12-30 2013-04-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Interleukin-12P40 variant with improved stability
BRPI0620795A2 (en) 2005-12-30 2011-11-22 Merck Patent Ges Mit Beschronkter Haftung anti-cd19 antibodies reduced immunogenicity
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
FR2907454B1 (en) * 2006-10-18 2009-01-23 Biomethodes Sa IMPROVED VARIANTS OF INTERFERON BETA HUMAIN
AU2007351813B2 (en) 2006-10-31 2013-10-10 East Carolina University Fusion proteins comprising an anti-inflammatory cytokine and an antigen for treatment of immune disorders
US8754194B2 (en) 2006-12-22 2014-06-17 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
DK2109457T3 (en) 2007-02-12 2016-04-11 Csl Behring Gmbh THERAPEUTIC USE OF KAZAL TYPE SERINE PROTEASE INHIBITORS
CA2685596A1 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
CN101361968B (en) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 Use of interleukin-22 in treating fatty liver
EP2853267B1 (en) 2007-09-21 2016-12-07 The Regents of the University of California Targeted interferon demonstrates potent apoptotic and anti-tumor activities
EP2203180B1 (en) * 2007-10-22 2012-11-21 Merck Serono S.A. Single ifn-beta fused to a mutated igg fc fragment
KR101507718B1 (en) 2008-06-24 2015-04-10 체에스엘 베링 게엠베하 Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
CA2757287C (en) 2009-03-31 2019-09-10 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
CN102405230A (en) * 2009-04-22 2012-04-04 默克专利有限公司 Antibody fusion proteins with modified fcrn binding sites
PT2506857T (en) 2009-12-01 2018-05-14 Translate Bio Inc Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
US20120308517A1 (en) 2010-02-09 2012-12-06 Digna Biotech, S.L. Compositions for the treatment of infectious and tumoural diseases
EP2371857A1 (en) 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
AR080993A1 (en) * 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd FORMULATION OF PROLONGED BETA INTERFERTION ACTION WHERE AN IMMUNOGLOBULIN FRAGMENT IS USED
CN102380091A (en) * 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 Application of interleukin-22 in curing virus hepatitis
WO2012065059A2 (en) * 2010-11-12 2012-05-18 The General Hospital Corporation Treatment of atherosclerosis with bmp-alk3 antagonists
CN102585013B (en) * 2011-01-07 2014-04-23 中国人民解放军军事医学科学院生物工程研究所 Fusion protein containing omega interferon and method for preparing same
CN103415301A (en) 2011-03-09 2013-11-27 德国杰特贝林生物制品有限公司 Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces
EP2497489A1 (en) 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
JP5977814B2 (en) 2011-04-08 2016-08-24 アムジエン・インコーポレーテツド Method for treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
SI2717893T1 (en) 2011-06-08 2019-10-30 Translate Bio Inc Lipid nanoparticle compositions and methods for mrna delivery
BR112014009925B1 (en) 2011-10-28 2022-09-20 Teva Pharmaceuticals Australia Pty Ltd POLYPEPTIDE BUILDERS AND THEIR USES
KR20130049671A (en) 2011-11-04 2013-05-14 한미사이언스 주식회사 Method for preparation of biological active polypeptide conjugate
US8936782B2 (en) * 2011-11-22 2015-01-20 Cedars-Sinai Medical Center Interferon beta as antibacterial agents
CN103182072B (en) 2011-12-27 2017-05-03 健能隆医药技术（上海）有限公司 Application of interleukin-22 in treating and preventing nerve injuries and neurodegeneration diseases
WO2013103981A1 (en) * 2012-01-06 2013-07-11 Ember Therapeutics, Inc. Compositions and methods of use of fndc5 polypeptides
EP2807266B1 (en) 2012-01-26 2020-01-15 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
AU2013216943B2 (en) 2012-02-10 2018-04-19 Research Corporation Technologies, Inc. Fusion proteins comprising immunoglobulin constant domain-derived scaffolds
PL2814502T3 (en) 2012-02-15 2018-02-28 Csl Behring Gmbh Von willebrand factor variants having improved factor viii binding affinity
AR090281A1 (en) 2012-03-08 2014-10-29 Hanmi Science Co Ltd IMPROVED PROCESS FOR THE PREPARATION OF A PHYSIOLOGICALLY ACTIVE POLYPEPTIDE COMPLEX
CA2862516C (en) 2012-03-27 2023-02-14 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
EP3536787A1 (en) 2012-06-08 2019-09-11 Translate Bio, Inc. Nuclease resistant polynucleotides and uses thereof
WO2014089354A1 (en) 2012-12-07 2014-06-12 The Regents Of The University Of California Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
SG11201504558TA (en) 2012-12-11 2015-07-30 Einstein Coll Med Methods for high throughput receptor:ligand identification
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
WO2014120619A2 (en) 2013-01-30 2014-08-07 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
WO2014124217A1 (en) * 2013-02-07 2014-08-14 Albert Einstein College Of Medicine Of Yeshiva University A selective high-affinity immune stimulatory reagent and uses thereof
WO2014128701A1 (en) 2013-02-20 2014-08-28 Yeda Research And Development Co. Ltd. Interferon treatment targeting mutant p53 expressing cells
ES2844189T3 (en) 2013-03-08 2021-07-21 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injuries
WO2014159813A1 (en) * 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
WO2014152940A1 (en) * 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
AU2014236396A1 (en) 2013-03-14 2015-08-13 Shire Human Genetic Therapies, Inc. Methods for purification of messenger RNA
KR102311614B1 (en) 2013-03-14 2021-10-08 샤이어 휴먼 지네틱 테라피즈 인크. Cftr mrna compositions and related methods and uses
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
EA033115B1 (en) 2013-04-29 2019-08-30 Тева Фармасьютикалз Острэйлиа Пти Лтд. Anti-cd38 antibodies and fusion proteins with attenuated interferon alpha-2b
WO2014194100A1 (en) 2013-05-29 2014-12-04 The Regents Of The University Of California Anti-cspg4 fusions with interferon for the treatment of malignancy
CA2918624C (en) * 2013-07-31 2024-02-13 Amgen Inc. Growth differentiation factor 15 (gdf-15) constructs
CN105658242A (en) 2013-10-22 2016-06-08 夏尔人类遗传性治疗公司 MRNA therapy for phenylketonuria
AU2014340092B2 (en) 2013-10-22 2019-09-19 Translate Bio, Inc. mRNA therapy for Argininosuccinate Synthetase Deficiency
CN104623637A (en) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Application of IL-22 dimer in preparation of intravenous injection drugs
PE20161096A1 (en) 2014-02-10 2016-10-22 Merck Patent Gmbh DIRECTED INHIBITION OF THE TRANSFORMING GROWTH FACTOR ß (TGFß)
US9738702B2 (en) 2014-03-14 2017-08-22 Janssen Biotech, Inc. Antibodies with improved half-life in ferrets
MY192248A (en) * 2014-03-31 2022-08-10 Hanmi Pharm Ind Co Ltd Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
CN110511927A (en) 2014-04-25 2019-11-29 川斯勒佰尔公司 The purification process of mRNA
UA119352C2 (en) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof
SG10202006338UA (en) * 2014-06-18 2020-08-28 Albert Einstein College Medicine Inc Syntac polypeptides and uses thereof
CA2953593C (en) 2014-07-02 2023-09-26 Csl Limited Modified von willebrand factor
EP3174894B1 (en) 2014-07-30 2021-06-23 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
EP3194429A4 (en) * 2014-09-18 2018-06-13 Askgene Pharma, Inc. Novel feline erythropoietin receptor agonists
CN107106656A (en) 2014-10-29 2017-08-29 梯瓦制药澳大利亚股份有限公司 Interferon alpha 2 b variant
NZ730054A (en) 2014-10-31 2023-11-24 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
KR101838919B1 (en) * 2015-03-03 2018-03-15 에이비온 주식회사 Immunocytokine conjugated with human interferon beta-mutein and method for preparing thereof
EP3298036B1 (en) 2015-05-22 2022-04-06 CSL Behring Lengnau AG Methods for preparing modified von willebrand factor
EP3297656B1 (en) 2015-05-22 2020-01-08 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
US11820807B2 (en) 2015-06-12 2023-11-21 Ubi Pharma Inc Immunoglobulin fusion proteins and uses thereof
US11891440B2 (en) * 2015-10-05 2024-02-06 Circle33 Llc Antibodies with improved stability to intestinal digestion, polynucleotides thereof and methods of use thereof to treat disease
EP3184149A1 (en) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Soluble glycoprotein v for treating thrombotic diseases
SG11201805497QA (en) 2016-01-07 2018-07-30 Csl Behring Recombinant Facility Ag Mutated truncated von willebrand factor
WO2017117630A1 (en) 2016-01-07 2017-07-13 Csl Limited Mutated von willebrand factor
EP3442562B1 (en) 2016-04-15 2022-09-21 Evive Biotechnology (Shanghai) Ltd An il-22 dimer for use in treating necrotizing enterocolitis
AU2017268348A1 (en) 2016-05-18 2018-10-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
WO2017201131A1 (en) 2016-05-18 2017-11-23 Albert Einstein College Of Medicine, Inc. Variant pd-l1 polypeptides, t-cell modulatory multimeric polypeptides, and methods of use thereof
JP7048608B2 (en) * 2016-08-15 2022-04-05 チルドレンズ メディカル センター コーポレーション APOM-FC fusion protein, a complex of it with sphingosine 1-phosphate (S1P), and methods for treating vascular and non-vascular diseases.
SG11201903950UA (en) 2016-11-11 2019-05-30 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
WO2018087271A1 (en) 2016-11-11 2018-05-17 Csl Behring Recombinant Facility Ag Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
IL308851A (en) 2016-12-22 2024-01-01 Cue Biopharma Inc T-cell modulatory multimeric polypeptides and methods of use thereof
WO2018129474A1 (en) 2017-01-09 2018-07-12 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
MA47603A (en) 2017-02-27 2020-01-01 Translate Bio Inc NEW ARNM CFTR WITH OPTIMIZED CODONS
CN111010875B (en) 2017-03-15 2024-04-05 库尔生物制药有限公司 Methods for modulating immune responses
JP7001285B2 (en) 2017-03-29 2022-01-19 国立大学法人 宮崎大学 Long-acting adrenomedulin derivative
PE20200150A1 (en) * 2017-04-21 2020-01-17 Genentech Inc USE OF KLK5 ANTAGONISTS FOR THE TREATMENT OF A DISEASE
IL270631B2 (en) 2017-05-16 2024-03-01 Translate Bio Inc Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
WO2018234518A1 (en) 2017-06-22 2018-12-27 CSL Behring Lengnau AG Modulation of fviii immunogenicity by truncated vwf
EP3737689A4 (en) 2018-01-09 2021-12-01 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
KR20200140878A (en) 2018-04-09 2020-12-16 암젠 인크 Growth differentiation factor 15 fusion protein
CN112930396A (en) 2018-08-24 2021-06-08 川斯勒佰尔公司 Method for purifying messenger RNA
KR20220009984A (en) 2019-05-17 2022-01-25 유니베르시태트 취리히 Haptoglobin for use in the treatment of secondary neurological adverse events after hemorrhagic stroke
WO2021001522A1 (en) 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
US20220348637A1 (en) 2019-11-11 2022-11-03 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
WO2021110071A1 (en) 2019-12-02 2021-06-10 The Hong Kong Polytechnic University Methods for inducing intermittent fasting and modulating autophagy
BR112022022035A2 (en) * 2020-04-29 2023-01-03 Abion Inc HUMAN INTERFERON-BETA VARIANT, POLYNUCLEOTIDE, EXPRESSION VECTOR, TRANSFORMED ANIMAL CELL, METHODS FOR PREPARING A HUMAN INTERFERON-BETA VARIANT, IMPROVING THE STABILITY OF A HUMAN INTERFERON-BETA R27T VARIANT, AND TREAT A DISEASE, PHARMACEUTICAL COMPOSITION AND USE
WO2021221470A1 (en) * 2020-04-29 2021-11-04 (주) 제노팜 Recombinant protein having fused interferon-beta mutein and antibody, and pharmaceutical composition comprising same
MX2022013208A (en) 2020-05-12 2022-11-14 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of use thereof.
WO2022162218A1 (en) 2021-02-01 2022-08-04 Csl Behring Ag Method of treating or preventing an adverse secondary neurological outcome following a haemorrhagic stroke
JPWO2022177018A1 (en) * 2021-02-22 2022-08-25
AU2022269297A1 (en) 2021-05-07 2023-12-07 Csl Behring Ag Expression system for producing a recombinant haptoglobin (hp) beta chain
WO2023039242A2 (en) * 2021-09-13 2023-03-16 Achelois Biopharma, Inc. Multivalent interferon particles compositions and methods of use
WO2024047219A1 (en) 2022-09-02 2024-03-07 Csl Behring Ag Haptoglobin for use in treating or preventing exaggerated erectile response or erectile dysfunction

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) * 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
WO2000023472A2 (en) * 1998-10-16 2000-04-27 Biogen, Inc. Interferon-beta fusion proteins and uses
WO2000069913A1 (en) * 1999-05-19 2000-11-23 Lexigen Pharmaceuticals Corp. EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS Fc FUSION PROTEINS
WO2001003737A1 (en) * 1999-07-13 2001-01-18 Bolder Biotechnology Inc. Immunoglobulin fusion proteins
WO2002074783A2 (en) * 2001-03-15 2002-09-26 Merck Patent Gmbh Modified interferon beta with reduced immunogenicity

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469797A (en) 1982-09-23 1984-09-04 Miles Laboratories, Inc. Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives
US4966843A (en) 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US5679543A (en) 1985-08-29 1997-10-21 Genencor International, Inc. DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi
EP0237019A3 (en) 1986-03-14 1988-03-09 Toray Industries, Inc. Interferon conjugate and production thereof using recombinant gene
US5019368A (en) 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
DE3853515T3 (en) 1987-05-21 2005-08-25 Micromet Ag MULTIFUNCTIONAL PROTEINS WITH SPECIFIC OBJECTIVES.
EP0294703B1 (en) 1987-06-10 1995-05-10 Dana-Farber Cancer Institute, Inc. Bifunctional antibody constructs and method for selectively destroying cell populations
US5064646A (en) 1988-08-02 1991-11-12 The University Of Maryland Novel infectious bursal disease virus
PH26813A (en) 1987-09-02 1992-11-05 Ciba Geigy Ag Conjugates of cytokines with immunoglobulins
EP0308936B1 (en) 1987-09-23 1994-07-06 Bristol-Myers Squibb Company Antibody heteroconjugates for the killing of HIV-infected cells
PT88641B (en) 1987-10-02 1993-04-30 Genentech Inc METHOD FOR PREPARING A VARIETY OF ADHESION
JP3040121B2 (en) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド Methods of treating tumor cells by inhibiting growth factor receptor function
CA1341588C (en) 1988-01-26 2009-01-06 Michel Revel Human ifn-beta2/i1-6, its purification and use
US5120525A (en) 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
IE62463B1 (en) 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5242824A (en) 1988-12-22 1993-09-07 Oncogen Monoclonal antibody to human carcinomas
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US6750329B1 (en) 1989-05-05 2004-06-15 Research Development Foundation Antibody delivery system for biological response modifiers
ATE123065T1 (en) 1989-07-07 1995-06-15 Takeda Chemical Industries Ltd PROTEINS AND THEIR PRODUCTION.
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
US5709859A (en) 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
US6072039A (en) 1991-04-19 2000-06-06 Rohm And Haas Company Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest
DE69227693T2 (en) 1991-08-30 1999-07-22 Hutchinson Fred Cancer Res HYBRID CYTOKINE
US20020037558A1 (en) 1991-10-23 2002-03-28 Kin-Ming Lo E.coli produced immunoglobulin constructs
US6627615B1 (en) 1991-12-17 2003-09-30 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
EP0615451B1 (en) 1992-05-26 2005-12-07 Immunex Corporation Novel cytokine that binds cd30
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5614184A (en) 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
DE69332485T2 (en) 1992-08-11 2003-11-13 Harvard College Immunomodulatory peptides
DE4228839A1 (en) 1992-08-29 1994-03-03 Behringwerke Ag Methods for the detection and determination of mediators
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
DE69523857T2 (en) 1994-09-16 2002-06-13 Merck Patent Gmbh immunoconjugates
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6169070B1 (en) 1995-03-10 2001-01-02 Genentech, Inc. Mer receptor activation by gas6
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
ATE218143T1 (en) 1996-09-03 2002-06-15 Gsf Forschungszentrum Umwelt USE OF BI- AND TRISPECIFIC ANTIBODIES TO INDUCE TUMOR IMMUNITY
US6100387A (en) 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
DK1037927T3 (en) 1997-12-08 2004-09-06 Emd Lexigen Res Ct Corp Heterodimeric fusion proteins useful for targeted immunotherapy and general immune stimulation
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
EP1071468B1 (en) 1998-04-15 2006-06-14 Lexigen Pharmaceuticals Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
CA2328081A1 (en) 1998-04-17 1999-10-28 Lexigen Pharmaceuticals Corporation Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor
AU751823B2 (en) 1998-05-14 2002-08-29 Merck Patent Gmbh Fused protein
CA2341029A1 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
BR9913331A (en) 1998-08-25 2001-05-15 Lexigen Pharm Corp Expression and export of angiogenesis inhibitors as immunofusins
US6646113B1 (en) 1998-09-17 2003-11-11 The Trustees Of The University Of Pennsylvania Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants
US6335176B1 (en) 1998-10-16 2002-01-01 Pharmacopeia, Inc. Incorporation of phosphorylation sites
AU778939B2 (en) 1999-01-07 2004-12-23 Emd Lexigen Research Center Corp. Expression and export of anti-obesity proteins as Fc fusion proteins
CN101173295A (en) 1999-05-06 2008-05-07 威克福雷大学 Compositions and methods for identifying antigens which elicit an immune response
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
ATE316982T1 (en) 1999-08-09 2006-02-15 Lexigen Pharm Corp MULTIPLE CYTOKINE ANTIBODIES COMPLEXES
US20050202538A1 (en) 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
EP1228214A2 (en) 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietin forms with improved properties
DE60122286T2 (en) 2000-02-11 2007-08-02 Merck Patent Gmbh INCREASING THE CIRCULATORY HALF-TIME OF ANTIBODY-BASED FUSION PROTEINS
PT1719528E (en) 2000-02-24 2012-01-06 Philogen Spa Compositions and methods for treatment of angiogenesis in pathological lesions
WO2001088117A2 (en) 2000-05-12 2001-11-22 Neose Technologies, Inc. In vitro fucosylation recombinant glycopeptides
BR0112111A (en) 2000-06-29 2003-05-06 Merck Patent Gmbh Enhancement of antibody-cytokine fusion protein-mediated immune responses by combined treatment with immunocytocin uptake enhancers
US20040043457A1 (en) 2001-01-18 2004-03-04 Silke Schumacher Bifunctional fusion proteins with glucocerebrosidase activity
MXPA03007323A (en) 2001-02-19 2003-12-12 Merck Patent Gmbh Artificial proteins with reduced immunogenicity.
ATE400030T1 (en) 2001-02-19 2008-07-15 Merck Patent Gmbh METHOD FOR IDENTIFYING T CELL PITOPES AND ITS APPLICATION TO PRODUCING MOLECULES WITH REDUCED IMMUNOGENICITY
CA2440221C (en) 2001-03-07 2013-02-05 Merck Patent Gesellschaft Mit Beschraenkter Haftung Expression technology for proteins containing a hybrid isotype antibody moiety
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
DE10119338A1 (en) * 2001-04-20 2002-10-24 Clariant Gmbh Use of copolymers based on acrylamidoalkylsulfonic acids as thickeners in preparations containing organic solvents
DE60239454D1 (en) 2001-05-03 2011-04-28 Merck Patent Gmbh RECOMBINANT, TUMOR-SPECIFIC ANTIBODY AND ITS USE
WO2003048334A2 (en) 2001-12-04 2003-06-12 Merck Patent Gmbh Immunocytokines with modulated selectivity
PL375045A1 (en) * 2002-02-21 2005-11-14 Wyeth Gasp1: a follistatin domain containing protein
US6938440B2 (en) * 2002-11-01 2005-09-06 Michele Smith Designs, Inc. Jewelry distribution and display combination and kit
CA2510180C (en) 2002-12-17 2012-09-11 Merck Patent Gesellschaft Mit Beschraenkter Haftung Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
US20050069521A1 (en) 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
US7435788B2 (en) * 2003-12-19 2008-10-14 Advanced Cardiovascular Systems, Inc. Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents
WO2005063820A2 (en) * 2003-12-30 2005-07-14 Merck Patent Gmbh Il-7 fusion proteins
EP1699821B1 (en) 2003-12-31 2012-06-20 Merck Patent GmbH Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
AU2005206277B2 (en) 2004-01-22 2011-06-23 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
KR20070085886A (en) 2004-12-09 2007-08-27 메르크 파텐트 게엠베하 Il-7 variants with reduced immunogenicity
US20070104689A1 (en) 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
JP5175214B2 (en) 2005-12-30 2013-04-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Interleukin-12P40 variant with improved stability
BRPI0620795A2 (en) 2005-12-30 2011-11-22 Merck Patent Ges Mit Beschronkter Haftung anti-cd19 antibodies reduced immunogenicity
JP2009521909A (en) 2005-12-30 2009-06-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Anti-IL-6 antibody that inhibits binding of IL-6 and IL-6Rα complex to gp130
ES2395969T3 (en) 2006-03-24 2013-02-18 Merck Patent Gmbh Genetically modified heterodimeric protein domains
AU2007271398B2 (en) 2006-07-06 2013-06-20 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) * 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
WO2000023472A2 (en) * 1998-10-16 2000-04-27 Biogen, Inc. Interferon-beta fusion proteins and uses
WO2000069913A1 (en) * 1999-05-19 2000-11-23 Lexigen Pharmaceuticals Corp. EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS Fc FUSION PROTEINS
WO2001003737A1 (en) * 1999-07-13 2001-01-18 Bolder Biotechnology Inc. Immunoglobulin fusion proteins
WO2002074783A2 (en) * 2001-03-15 2002-09-26 Merck Patent Gmbh Modified interferon beta with reduced immunogenicity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAY C ET AL: "ENGINEERED DISULFIDE BOND GREATLY INCREASES SPECIFIC ACTIVITY OF RECOMBINANT MURINE INTERFERON- BETA", JOURNAL OF INTERFERON RESEARCH, MARY ANN LIEBERT, INC., NEW YORK, NY, US, vol. 12, no. 2, 1 April 1992 (1992-04-01), pages 139 - 143, XP000647532, ISSN: 0197-8357 *
LO K-M ET AL: "High level expression and secretion of Fc-X fusion proteins in mammalian cells", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 11, no. 6, June 1998 (1998-06-01), pages 495 - 500, XP002125745, ISSN: 0269-2139 *
RUNKEL LAURA ET AL: "Systematic mutational mapping of sites on human interferon-beta-1a that are important for receptor binding and functional activity", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 39, no. 10, 14 March 2000 (2000-03-14), pages 2538 - 2551, XP002160244, ISSN: 0006-2960 *
STEWART A G ET AL: "CHEMICAL MUTAGENESIS OF HUMAN INTERFERON-BETA: CONSTRUCTION, EXPRESSION IN E. COLI, AND BIOLOGICAL ACTIVITY OF SODIUM BISULFITE-INDUCED MUTATIONS", DNA, MARY ANN LIEBERT, NEW YORK, NY, US, vol. 6, no. 2, April 1987 (1987-04-01), pages 119 - 128, XP009004161, ISSN: 0198-0238 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103570836A (en) * 2013-10-25 2014-02-12 江苏众红生物工程创药研究院有限公司 Recombinant porcine interferon beta1-Fc fusion protein as well as encoding gene and expressing method thereof
CN103570836B (en) * 2013-10-25 2016-03-16 江苏众红生物工程创药研究院有限公司 A kind of Recombinant Swine interferon beta 1-Fc fusion rotein and encoding gene thereof and expression method
CN104530213A (en) * 2014-11-24 2015-04-22 广西大学 Viral hepatitis treatment drug interferon production technology

Also Published As

Publication number Publication date
US7670595B2 (en) 2010-03-02
AU2005256519A1 (en) 2006-01-05
US20090191154A1 (en) 2009-07-30
EP1761559B1 (en) 2009-09-23
CA2572015A1 (en) 2006-01-05
WO2006000448A2 (en) 2006-01-05
US8557232B2 (en) 2013-10-15
ATE443720T1 (en) 2009-10-15
AU2005256519B2 (en) 2011-10-13
CA2572015C (en) 2014-04-22
US20140005361A1 (en) 2014-01-02
EP1761559A2 (en) 2007-03-14
JP4808709B2 (en) 2011-11-02
JP2008508862A (en) 2008-03-27
US20060228332A1 (en) 2006-10-12
ES2332924T3 (en) 2010-02-15
DE602005016799D1 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
WO2006000448A3 (en) Fc-INTERFERON-BETA FUSION PROTEINS
WO2007110231A3 (en) MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
WO2005077042A3 (en) Albumin fusion proteins
WO2007021494A3 (en) Albumin fusion proteins
EP2277889A3 (en) Fusion proteins of albumin and interferon beta
WO2005063820A3 (en) Il-7 fusion proteins
AU2003263552A8 (en) Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
DE60311567D1 (en) TRICYCLIC PYRAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS ANTITUMOR AGENTS
PT1641483E (en) Fusion proteins
WO2008033413A3 (en) Albumin fusion proteins
WO2007146038A3 (en) Albumin fusion proteins
EP1276756A1 (en) Albumin fusion proteins
DE10290072D2 (en) Modular transfection systems
WO2005037211A3 (en) Methods and compositions for the treatment of neurological disease
WO2003097810A3 (en) Nitrilases, nucleic acids encoding them and methods for making and using them
WO2007149594A3 (en) Modified ribonucleases
MXPA05008688A (en) Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them.
WO2006047728A3 (en) Bmp gene and fusion protein
AU2003281619A1 (en) aPC NON-NEUTRALIZING ANTIBODY
WO2004009024A3 (en) Modulation of protein kinase c-iota expression
WO2004081229A3 (en) Use of bv8 and/or eg-vegf to promote hematopoiesis
WO2006122971A3 (en) Treatment of disease using an improved regulated expression system
WO2001040313A3 (en) Feline immunoregulatory proteins, nucleic acid molecules, and uses thereof
WO2010065536A3 (en) Recombinant bone marrow stromal antigen-2 in the treatment of autoimmune diseases
EA200700346A1 (en) BACTERIOPHAG- AND PROFAG-SPECIFIC PROTEINS IN CANCER GENETIC THERAPY

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005766761

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2572015

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007517216

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005256519

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2005256519

Country of ref document: AU

Date of ref document: 20050628

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005256519

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005766761

Country of ref document: EP